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Determination of the role of steroid hormones in expression and regulation of endometrial glucose transport 4
(GLUT4) in humans is important for understanding endometrial disorders such as polycystic ovary syndrome
(PCOS), a common hormone-imbalance disease.
Methods
Endometrial biopsy sampleswere collected fromnon-PCOSpatientswith regularmenstrual cycles orwith hyper-
plasia and from PCOS patientswith orwithout hyperplasia. In addition, endometrial tissues frompostmenopaus-
al women were incubated with human chorionic gonadotropin (hCG, 10 IU/ml), 17β-estradiol (E2, 10 nM),
progesterone (P4, 100 nM), or a combination of E2 and P4 for 24 h. The expression of GLUT4 was measured at
the mRNA level using quantitative real-time polymerase chain reaction (qRT-PCR) and at the protein level
using Western blot analysis and immunohistochemistry.
Results
A cyclical change in GLUT4 expression pattern was observed in non-PCOS patients, and a high level of GLUT4 ex-
pression was seen in the proliferative phase compared to the secretory phase. Low levels of GLUT4 expression
were found in PCOS patients compared to menstrual cycle phase-matched non-PCOS patients, and there was
no signiﬁcant change in GLUT4 expression in PCOS patients during the menstrual cycle. GLUT4 was localized
in both epithelial and stromal cells, with notable changes in epithelial cells. We postulate that decreased
GLUT4 expression might be regulated by steroid hormones. In support of this, we showed that in cultured endo-
metrial tissues hCG and E2 alone had no effect on GLUT4 expression. However, P4 alone and P4 in combination
with E2 decreasedGLUT4 expression. Comparedwith non-PCOS controls, PCOS patientswith endometrial hyper-
plasia exhibited decreased GLUT4 expression in particular in the epithelial cells.
Conclusion
We conclude that P4 can induce changes in endometrial GLUT4 expression during the menstrual cycle and that
abnormal hormonal conditions such as PCOS disrupt normal patterns of GLUT4 expression in endometrial cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The human endometrium includes epithelial cells, stromal cells, im-
mune cells, and blood vessels [1], and both epithelial and stromal cellsff/ruijin_shao/ (R. Shao).
. This is an open access article underare exquisitely sensitive to steroid hormone stimulation in women dur-
ing the menstrual cycle [2]. In addition to estrogen and progesterone,
human uterine ﬂuid contains blood-derived glucose that is required
for ATP synthesis [3,4], and the link between glucose metabolism, im-
plantation, embryonic development, and pregnancy has been recog-
nized [5,6]. There is an increasing body of evidence indicating that
glucose transporters (GLUTs) are responsible for the transport of glu-
cose across the cell membrane and that they regulate glucose utilization
in tissues and cells [5]. A number of GLUTs with different tissuethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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humans and rodents [5]. Among them, GLUT4 (SLC2A4) is a dynamic
modulator of normal glucose homeostasis in adipose and muscle tis-
sues, and dysfuntion of GLUT4 leads to insulin resistance and type 2 di-
abetes [7]. Although GLUT4 mRNA and protein has been described in
human and rodent endometria and uterine stromal cells [8–12], the
ﬁnding of detectable levels of GLUT4 mRNA and protein in uterine
cells in humans and rodents under physiological and pathological con-
ditions is somewhat puzzling [8,13–15].
Polycystic ovary syndrome (PCOS) is the most common hormone-
imbalance disorder [16], and it affects 4%–18% of adolescent and
reproductive-aged women worldwide [17]. It is frequently associated
with adverse impacts on female reproduction [16,18], such as recurrent
pregnancy loss [19] and irregular cycle-induced anovulation infertility
[20]. It is generally believed that the failure of reproductive success in
PCOS patients is in part due to endometrial dysfunction [21]. Previous
studies from our group and other laboratories have shown aberrant ex-
pression of endometrial GLUT4mRNA and protein inwomenwith PCOS
[10,14,22–25]. While in vitro experiments have shown that testoster-
one decreases GLUT4 expression in human endometrial epithelial cells
[26], there is no direct evidence to clarify whether 17β-estradiol (E2)
or progesterone (P4) or both are involved in the regulation of endome-
trial GLUT4 expression under normal conditions or under disease condi-
tions such as endometrial hyperplasia.
Given the evidence for menstrual cycle-dependent regulation of en-
dometrial GLUT4 expression [11], we set out to elucidate the cellular
pattern of endometrial GLUT4 expression in women with and without
PCOS during the menstrual cycle and under conditions of endometrial
hyperplasia. Furthermore, we evaluated the effects of physiological
doses of E2 and P4 on endometrial GLUT4 expression in order to deter-
mine which steroid hormone might contribute to the regulation of
GLUT4 expression.
2. Materials and methods
2.1. Reagents and antibodies
Human chorionic gonadotropin (hCG) was from NV Organon (Oss,
Holland). 17β-estradiol (E2), progesterone (P4), and 3,3-Diaminobenzi-
dine tetrahydrochloride (DAB) were from Sigma-Aldrich (St. Louis,
MO). The Avidin-biotinylated-peroxidase complex detection system
(ABC kit) was from Vector Laboratories Inc. (Burlingame, CA). All anti-
bodies were from the following sources: GLUT4 (ab33780) antibody
was from Abcam (Cambridge, UK), cytokeratin 8/18 (#4546) antibody
was from Cell Signaling Technology (Danvers, MA); estrogen receptor
alpha (ERα, #6F11) and progesterone receptor A/B (PRA and PRB,
#16) antibodies were from Novocastra Laboratories (Newcastle, UK);
and estrogen receptor beta (ERβ, PPG5/10) antibody was from AbD
Serotec (Oxford, UK). β-actin (P-0130), anti-mouse IgG horseradish
peroxidase (HRP)-conjugated goat (A2304), and anti-rabbit IgG HRP-
conjugated goat (A0545) secondary antibodies were from Sigma-
Aldrich.
2.2. Human tissue samples
Endometrial biopsies for in vivo studies were obtained by curettage
from the Obstetrics and Gynecology Hospital of Fudan University,
Shanghai, with the approval of the institutional review board. Each en-
dometrial sample was diagnosed and staged by routine pathology anal-
ysis based on standard histological criteria [27], and the patient's last
reported menstrual period was recorded at the time of collection.
PCOS was diagnosed based on the Rotterdam criteria provided by the
American Society for Reproductive Medicine and the European Society
for Human Reproduction and Embryology [28]. All fertile women
(n = 19) at the proliferative (n = 13, aged 23–44 years) or secretory
phases of the menstrual cycle (n = 3, aged 30–41 years) or withhyperplasia (n = 3, aged 25–43 years) taking part in the investigation
had regular menstrual cycles and showed no evidence of any patholog-
ical uterine disorder. Endometrial biopsies were obtained from PCOS
patients (n = 13) at the proliferative (n = 8, aged 26–36 years) and
secretory phases of the menstrual cycle (n = 2, aged 28 and 40 years)
or from PCOS patients with hyperplasia (n = 3, aged 26–28 years). A
diagnosis of PCOS was made if at least two of the following criteria
were met: 1) oligo/anovulation, 2) signs of hyperandrogenism
(i.e., hirsutism and acne) and/or biochemical measurements, or 3) en-
hanced ovaries (at least 12 discrete follicles of 2–9 mm in diameter in
one ovary or an ovarian volume N10 cm3 observed by transvaginal ul-
trasonography). Women with other androgen-excess disorders or spe-
ciﬁc etiologies including congenital adrenal hyperplasia, Cushing's
syndrome, thyroid hormone abnormalities, hyperprolactinemia, or
ovarian/adrenal tumorswere excluded. All PCOS patients hadnohistory
of previousﬁrst-trimestermiscarriage or pregnancy. No patients had re-
ceived exogenous hormonal therapy for at least three months before
the procedure. All tissue samples were washed with ice-cold RNase-
free phosphate-buffered saline (PBS) and either snap-frozen in liquid
nitrogen and stored at−70 °C or ﬁxed in 4% formaldehyde and embed-
ded in parafﬁn.
Endometrial tissues from postmenopausal women (n = 7, aged
63–73 years) for in vitro studies were obtained by hysterectomy. The
collection and processing steps have been described [29]. Two small
pieces (3 × 5 × 5mm), containing the endometrium and the underlying
myometrium,were excised from the lower uterine cavity, and the endo-
metrium was gently isolated. The study was approved by the Research
Ethics Committee at the University of Gothenburg and was conducted
at the Sahlgrenska Academy, University of Gothenburg, in accordance
with the Declaration of Helsinki for medical research involving human
subjects. Informed consent was obtained from all patients.
2.3. Endometrial tissue culture and treatment
The culture condition andmethods, including reagents used, are de-
scribed in [30]. After washing in PBS, endometrial tissues were cut into
~1 × 2-mm2 sections with a ﬁne scalpel under a stereomicroscope. Tis-
sues were treated with 10 IU/ml hCG, 10 nME2, 100 nMP4, or a combi-
nation of 10 nM E2 and 100 nM P4, and the tissues were cultured in
RPMI-1640 medium (Sigma-Aldrich) with 10% fetal calf serum and
100 IU/ml penicillin/streptomycin (GIBCO-BRL, San Francisco, CA) at
37 °C in a fully humidiﬁed 5% CO2 atmosphere for 24 h. The selected
physiological doses of hCG, E2, and P4 were previously found to ensure
the effects mediated by luteinizing hormone receptors, ERs, or PRs in
human endometrial tissues in vitro [30]. E2 and P4 were dissolved in
100% ethanol at a concentration of 50mMand added to culturemedium
to achieve the desired ﬁnal concentration. Controls were treated with
100% ethanol. At the end of the experiments, cultured tissues were
snap-frozen in liquid nitrogen and stored at−70 °C or ﬁxed in 4% form-
aldehyde and embedded in parafﬁn.
2.4. RNA extraction and quantitative real-time PCR analysis
Quantitative real-time RT-PCR (qRT-PCR) was performed with an
ABI PRISM 7900 sequence detection system (Applied Biosystems, Foster
City, CA). The PCR parameters were set according to themanufacturer's
protocols, and ampliﬁcations were performed with a SYBR®Premix Ex
Taq kit (#RR420A, Takara Bio Inc., Shiga, Japan). Tissues from the endo-
metrium of each patient were digested with RNase-free DNase I
(Ambion) to remove genomic DNA. Total RNA was isolated from indi-
vidual tissues using Trizol Reagent (Life Technologies) according to
themanufacturer's instructions. Single-stranded cDNAwas synthesized
from each sample (1 μg) with PrimeScript RT Master Mix (#RR036A,
Takara Bio Inc.). cDNA (1 μl) was added to a reaction master mix
(10 μl) containing 2× SYBR Green PCR reaction mix (Takara Bio Inc.)
and gene-speciﬁc primers (10 μMeach of forward and reverse primers).
Table 1
Primers used for quantitative real-time PCR analyses.
Gene Primer Size Reference
SLC2A4 (GLUT4)
Forward ATCCTTGGACGATTCCTCATTGG
90 bp This studyReverse CAGGTGAGTGGGAGCAATCT
SLC2A4 (GLUT4)
Forward GCCATGAGCTACGTCTCCATT
90 bp This studyReverse GGCCACGATGAACCAAGGAA
SLC2A4 (GLUT4)
Forward CTACAATGAGACGTGGCTGG
160 bp This studyReverse CCTTCCAAGCCACTGAGAGA
SLC2A4 (GLUT4)
Forward TGCAGTTTGGGTACAACATTGG
190 bp [13]Reverse ATGAGGAAGGAGGAAATCATGC
SLC2A4 (GLUT4)
Forward GCCCGAAAGAGTCTAAAG
407 bp [25]Reverse AGAGCCACGGTCATCAAG
ACTB (β-actin)
Forward CATGTACGTTGCTATCCAGGC
250 bp This studyReverse CTCCTTAATGTCACGCACGAT
CYC1 (Cytochrome c isoform 1)
Forward AGCTATCCGTGGTCTCACC
225 bp This studyReverse CCGCATGAACATCTCCCCATC
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All primers (Table 1) were designed to exclude the ampliﬁcation of ge-
nomic DNA. Ampliﬁcation qualitywas validated by analysis of themelt-
ing curve. All reactions were performed in duplicate, and each reaction
included a non-template control. The CT values for both ACTB (β-actin)
and CYC1 (Cytochrome c isoform 1) were not signiﬁcantly different in
any of the groups, which conﬁrmed that the loading was similar be-
tween the samples. The result for GLUT4 gene is expressed as the
amount relative to the average value of β-actin + CYC1 in each sample.
Relative gene expression was determined with the 2−(ΔΔCT) method.
2.5. Western blot analysis
Endometrial tissues were lysed using RIPA buffer (Sigma-Aldrich)
supplemented with cOmplete Mini protease inhibitor cocktail tablets
(Roche Diagnostics, Mannheim, Germany) and PhosSTOP phosphatase
inhibitor cocktail tablets (Roche Diagnostics). After incubation for
15 min on ice, tissue lysates were cleared by centrifugation atFig. 1. Expression of GLUT4 mRNA and proteins in the endometrium from non-PCOS and PCOS
and qRT-PCR andWestern blot assays were performed as described in the Materials and Metho
tween non-PCOS and PCOS patients. RNA levels were normalized to the average level of ACTB (
icant (p N 0.05). (B) RepresentativeWestern blot analysis of GLUT4 expression in human endom
of whether hyperplasia was present. Cytokeratin 8 (an epithelial cell marker) and β-actin wer10,000 ×g for 30min at 4 °C, and the protein concentration of the super-
natant was determined with a Direct Detect® spectrometer (EMD
Millipore Corporation, Billerica, MA). A detailed explanation of the
Western blot analysis protocol has been published elsewhere [31].
Equal amounts of protein for each treatment group were resolved on
NuPAGE 4–12% Bis–Tris gels (Invitrogen) and transferred onto PVDF
membranes. The membranes were probed with the primary antibody
(1:1000–2000 dilution) of interest in 0.01 M Tris-buffered saline sup-
plemented with Triton X-100 (TBST) containing 5% nonfat dry milk
followed by HRP-conjugated secondary antibody. When necessary,
PVDFmembraneswere stripped using Restore PLUSWestern blot strip-
ping buffer (Thermo Scientiﬁc, Rockford, IL) for 15min at room temper-
ature, washed twice in TBST, and then reprobed.
2.6. Immunohistochemistry
Immunohistochemistry was based on the previously described
methodology [32]. The tissues were ﬁxed in 4% formaldehyde neutral-patients. Endometrial homogenates were prepared fromwomen with and without PCOS,
ds. (A) Quantitative RT-PCR analysis of GLUT4 mRNA levels in the proliferative phase be-
β-actin) and CYC1 (cytochrome c isoform 1). Values are the mean ± SEM. N.S., nonsignif-
etrial tissues in vivo. The level of GLUT4 proteinwas decreased in PCOS patients regardless
e used as the internal controls.
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tion, the sectionswere immersed in epitope retrieval buffer (10mM so-
dium citrate buffer, pH 6.0) and heated in a 700 Watt microwave for
10 min. The sections were subsequently rinsed twice with dH2O and
once with TBST. The endogenous peroxidase and nonspeciﬁc binding
were removed by incubationwith 3%H2O2 for 10min andwith 10%nor-
mal goat serum for 1 h at room temperature. After incubation with the
GLUT4 primary antibody (1:100 dilution) overnight at 4 °C in a humid-
iﬁed chamber, sections were stained using the avidin-biotinylated-
peroxidase ABC kit according to the manufacture's instruction (Vector
Laboratories) followed by a 5-min treatment with DAB-Ni (SK-4100,
Vector Laboratories). Sections were imaged on a Nikon E-1000 micro-
scope (Japan) under bright ﬁeld optics and photomicrographed using
Easy Image 1 (Bergström Instrument AB, Sweden).Fig. 2.Comparison of immunohistochemical staining of GLUT4 in the endometrium fromnon-PC
liferative phase ofwomenwithout PCOS (A1) andwith PCOS (A2), in the secretory phase ofwom
(C1) and in women with both PCOS and hyperplasia (C2). The same concentration of rabbit Ig
Enhanced magniﬁcations are shown in the bottom right corner of A1–D. Immunohistochemist
dometrial cell types, and speciﬁc immunostaining of GLUT4 (DAB-Ni-black) was detected ma
numerous sections from multiple endometrial tissues. Scale bar = 100 μm. Ge, glandular epith2.7. Statistical analysis
Results are presented asmeans±SEM. Statistical analyseswere per-
formed using SPSS version 21.0 statistical software for Windows (SPSS
Inc., Chicago, IL). For the in vivo studies, unpaired Student's t-test was
used to compare two groups. For the in vitro studies, datawere analyzed
using one-way ANOVA followed by Dunnett's post-hoc tests. A p-value
less than 0.05 was considered statistically signiﬁcant.
3. Results and discussion
Menstrual dysfunction is a major cause of infertility [33], and men-
strual cycle irregularities and disturbances are the key feature of PCOS
[16,18]. We showed that endometrial GLUT4 expression is higher inOSand PCOSpatients. Representative parafﬁn-embedded endometrial sections in the pro-
enwithout PCOS (B1) andwith PCOS (B2), and inwomenwith hyperplasiawithout PCOS
G instead of the primary and secondary antibodies was used as the negative control (D).
ry was performed as described in the Materials and Methods. GLUT4 was found in all en-
inly in the membrane and cytoplasm. The images are representative of those observed in
elial cells; Str, stromal cells.
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in non-PCOS patients (Fig. 1B), which is in accordance with a previous
report [11]. In the proliferative phase, a signiﬁcant reduction in endo-
metrial GLUT4 protein (Fig. 1B) but not mRNA (Fig. 1A) expression
was observed in PCOS patients compared to non-PCOS patients. More-
over, only endometrial GLUT4 protein expression was being shown as
constant throughout the menstrual cycle in PCOS patients (Fig. 1B and
2). This indicates that in non-PCOS women, different hormone environ-
ments during themenstrual cycle inﬂuence endometrial GLUT4, in con-
trast to women with PCOS.
It iswell established that steroid hormones (E2 and P4) and their nu-
clear receptors (ERα, ERβ, PRA, and PRB) [34,35] are tightly regulated
during the menstrual cycle [2]. Furthermore, it is increasingly apparent
that E2 and P4 can exert their effects through cell-membrane bound ERs
and PRs. Indeed, several membrane-bound ERs [36,37] and PRs [38,39]
have been reported to be expressed in human endometrium. The regu-
latory pattern for endometrial GLUT4 expression in women during the
menstrual cycle has been established [11], sowe next examinedwheth-
er E2 and/or P4 regulates endometrial GLUT4 regulation. In the cultured
endometrial tissues, Western blot analysis (Fig. 3) showed that E2 de-
creased ERα expression, increased PRA and PRB expression, and had
no effect on GLUT4 and ERβ expression. In contrast, P4 decreased
GLUT4 expression and increased ERα and PRA/B expression. Additional-
ly, the combined treatmentwith E2 and P4had a similar effect onGLUT4
expression as P4 alone. P4 has previously been shown to inhibit insulin-
regulated glucose uptake by decreasing GLUT4 expression in 3T3-L1 ad-
ipocytes [40]. Previous studies have also shown that E2 and ER agonists
decrease GLUT4 expression in 3T3-L1 adipocytes [41,42] in contrast to
human skeletal muscle cells [43]. Moreover, treatment with testoster-
one decreases GLUT4 protein expression in human endometrial epithe-
lial cells in vitro [26]. Together, these data suggest that regulation of
GLUT4 expression is steroid hormone-speciﬁc and tissue/cell-speciﬁc
under physiological conditions.
Because the proliferation, differentiation, secretion, and apoptosis of
endometrial cells are controlled by steroid hormones [2], and given the
fact that glucose uptake and utilization play a crucial role inFig. 3. Effects of gonadotropin and steroid hormones on GLUT4 protein levels in cultured hum
treated with vehicle, hCG, E2, P4, or E2 + P4 for 24 h. Tissue lysates were directly immunoblot
blot assay was performed as described in theMaterials andMethods. β-actinwas used as an int
gonadotropin; E2, 17β-estradiol; P4, progesterone; ERα, estrogen receptor alpha; ERβ, estrogeimplantation, embryonic development, and pregnancy [5,6], it remains
to be determined how endometrial GLUT4 contributes to glucose me-
tabolism in response to P4 stimulation under physiological conditions
in vivo. On the other hand, the observation that decreased endometrial
GLUT4 expression by P4 stimulation is surprising, especially because the
endometria in PCOS patients tend to remain in a proliferative state due
to the lack of counterbalance by P4 [44]. It has been shown that insulin/
insulin receptor signaling has a metabolic function and favors glucose
uptake in the endometrial cells [11,45]. Although themolecularmecha-
nisms underlying insulin resistance in PCOS remain elusive, insulin re-
sistance in these patients is believed to contribute to endometrial
dysfunction [16,46]. Because GLUT4 is an insulin-responsive glucose
transporter [5], and because therapeutic insulin sensitizers such asmet-
formin increase endometrial GLUT4 expression in vivo and in vitro [10,
22], our current ﬁndings support the view that the regulation of endo-
metrial GLUT4 expression does not depend solely on steroid hormones
in PCOS patients. Understanding the speciﬁc effects of insulin on endo-
metrial GLUT4 expression will required additional investigation.
Although the expression of GLUT4 mRNA and protein in endometri-
al stromal cells under physiological conditions is more controversial [8,
13,23], our immunohistochemistry and immunoﬂuorescence analysis
[10] showed that GLUT4 immunoreactivity was present in human
endometrial stromal cells under physiological conditions. We also
showed that in addition to epithelial cells, stromal GLUT4 immunoreac-
tivity was detectable and variable in cultured human endometrial tis-
sues treated with hCG, E2, and P4 (Fig. 4). Moreover, a previous
in vitro study indicated that GLUT4 protein levels can be detected by
Western blot analysis in human endometrial stromal cells [47]. Based
on our ﬁnding that GLUT4 expression was decreased in both epithelial
and stromal cells in response to P4 alone and in combination with E2,
we speculate that GLUT4 plays a unique role in endometrial epithelial
and stromal cells.
A prospective cross-sectional study showed that hyperinsulinemia
is often associated with endometrial hyperplasia [48]. Extensive evi-
dence in the literature indicates that both insulin resistance and conse-
quent hyperinsulinemia have an important role in the pathogenesis ofan endometrial tissues. Endometrial biopsy samples from postmenopausal women were
ted with antibodies to GLUT4, ERα, ERβ, PRA, PRB, and β-actin as indicated. The Western
ernal control. Values are themean± SEM. ** p b 0.01; *** p b 0.001. hCG, human chorionic
n receptor beta; PRA, progesterone receptor A; PRB, progesterone receptor B.
Fig. 4. Comparison of immunohistochemical staining for GLUT4 in cultured human endometrial tissues. Endometrial biopsy samples from postmenopausal womenwere treatedwith ve-
hicle (A1, A2), hCG (B1, B2), E2 (C1, C2), P4 (D1, D2), or E2+ P4 (E1, E2) for 24 h,ﬁxed in formalin, and embedded in parafﬁn. The same concentration of rabbit IgG instead of the primary
and secondary antibodies was used as the negative control (F). Enhancedmagniﬁcations are shown on the right of A1–F. Immunohistochemistry was performed as described in the Ma-
terials andMethods. Speciﬁc immunostaining of GLUT4 (Ni-black) was detectedmainly in themembrane and cytoplasm. Representative images (n=3 patients) from three independent
experiments are shown. Scale bar = 100 μm. hCG, human chorionic gonadotropin; E2, 17β-estradiol; P4, progesterone; Ge, glandular epithelial cells; Str, stromal cells.
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trial GLUT4 expression was lower in PCOS patients than non-PCOS pa-
tients with hyperplasia. In addition, immunohistochemistry (Fig. 2)
indicated that PCOS rather than hyperplasia conditions appear to
have a major effect on GLUT4 expression in epithelial cells. While
PCOS patients with endometrial hyperplasia are often associated with
progesterone and insulin resistance [16,18,44], our data suggest that
aberrant expression of GLUT4 might be useful in distinguishing PCOS
patients with endometrial hyperplasia from non-PCOS patients with
endometrial hyperplasia.
Before we conclude some of themajor implication of our ﬁndings,
a limitation of the study needs to mention. Our study has included
the relatively small sizes of the patient groups. Thus future random-
ized trials with a larger sample size are needed to conﬁrm our
ﬁndings.4. Conclusion
PCOS is a complex and heterogeneous disease process that in-
volves different pathophysiological mechanisms [16,46]. Although
our patient cohort was small and a larger study is needed for valida-
tion, our study provides in vivo and in vitro evidence showing that
endometrial GLUT4 expression depends on the menstrual cycle
phase and the presence of PCOS. Endometrial cells can be targeted
for regulating GLUT4 expression under different hormonal condi-
tions, and we hypothesize that steroid hormone-dependent regula-
tion of GLUT4 expression might be part of the mechanism behind
PCOS-induced endometrial dysfunction. Therefore, it will be impor-
tant in future studies to elucidate cellular and molecular mechanism
underlying speciﬁc hormone-regulated GLUT4 expression in human
endometrium.
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